HOXA10 regulates p53 expression and matrigel invasion in human breast cancer cells

被引:105
作者
Chu, MC [1 ]
Selam, FB [1 ]
Taylor, HS [1 ]
机构
[1] Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06511 USA
关键词
breast cancer; HOXA10; p53; estradiol; tamoxifen;
D O I
10.4161/cbt.3.6.848
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
HOX genes regulate cell differentiation during embryonic development. Here we demonstrate HOXA10 expression in both benign and malignant adult human breast tissue and in MCF-7, but not BT20 breast cancer cells. We have previously shown that HOXA10 mediates uterine differentiation in response to estrogens. The mechanism of action of estradiol and other estrogen receptor modulators on breast cancer cell growth is still poorly understood. MCF-7 cells, which are ER (+) and express HOXA10, were used to assay the effect of estradiol and tamoxifen on HOXA10 expression. Semi-quantitative RT-PCR and northern analysis revealed that treatment with either estradiol or tamoxifen increased HOXA10 mRNA expression. BT20 cells, which are ER (-) and do not endogenously express HOXA10, were used to assay the effect of increased HOXA10 expression on p53 expression and on the invasive phenotype. Constitutively expressing HOXA10 in BT20 cells increased p53 protein expression. Increased HOXA10 also reduced invasiveness through matrigel. The mechanism by which estrogen and other estrogen receptor modulators influence both normal breast development as well as breast cancer may involve the regulation of developmental control genes such as HOXA10; HOXA10 in turn regulates expression of key downstream genes such as p53 and regulates tumor cell functional phenotype.
引用
收藏
页码:568 / 572
页数:5
相关论文
共 33 条
  • [21] Prives C, 1999, J PATHOL, V187, P112
  • [22] Compromised HOXA5 function can limit p53 expression in human breast tumours
    Raman, V
    Martensen, SA
    Reisman, D
    Evron, E
    Odenwald, WF
    Jaffee, E
    Marks, J
    Sukumar, S
    [J]. NATURE, 2000, 405 (6789) : 974 - 978
  • [23] Transcriptional regulation of the p53 tumor suppressor gene
    Reisman, D
    Loging, WT
    [J]. SEMINARS IN CANCER BIOLOGY, 1998, 8 (05) : 317 - 324
  • [24] HUMAN P53 ONCOGENE CONTAINS ONE PROMOTER UPSTREAM OF EXON-1 AND A 2ND, STRONGER PROMOTER WITHIN INTRON-1
    REISMAN, D
    GREENBERG, M
    ROTTER, V
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (14) : 5146 - 5150
  • [25] Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial
    Rossouw, JE
    Anderson, GL
    Prentice, RL
    LaCroix, AZ
    Kooperberg, C
    Stefanick, ML
    Jackson, RD
    Beresford, SAA
    Howard, BV
    Johnson, KC
    Kotchen, JM
    Ockene, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (03): : 321 - 333
  • [26] Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4:11) abnormality
    Rozovskaia, T
    Feinstein, E
    Mor, O
    Foa, R
    Blechman, J
    Nakamura, T
    Croce, CM
    Cimino, G
    Canaani, E
    [J]. ONCOGENE, 2001, 20 (07) : 874 - 878
  • [27] HoxA9-mediated immortalization of myeloid progenitors requires functional interactions with TALE cofactors Pbx and Meis
    Schnabel, CA
    Jacobs, Y
    Cleary, ML
    [J]. ONCOGENE, 2000, 19 (05) : 608 - 616
  • [28] Homeobox gene Cdx1 regulates Ras, Rho and PI3 kinase pathways leading to transformation and tumorigenesis of intestinal epithelial cells
    Soubeyran, P
    Haglund, K
    Garcia, S
    Barth, BU
    Iovanna, J
    Dikic, I
    [J]. ONCOGENE, 2001, 20 (31) : 4180 - 4187
  • [29] HUMAN CELL LINE FROM A PLEURAL EFFUSION DERIVED FROM A BREAST CARCINOMA
    SOULE, HD
    VAZQUEZ, J
    LONG, A
    ALBERT, S
    BRENNAN, M
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1973, 51 (05) : 1409 - 1416
  • [30] HOXA10 is expressed in response to sex steroids at the time of implantation in the human endometrium
    Taylor, HS
    Arici, A
    Olive, D
    Igarashi, P
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (07) : 1379 - 1384